Analyst Gil Blum from Needham maintained a Buy rating on Recursion Pharmaceuticals (RXRX – Research Report) and keeping the price target ...

Sanofi is end­ing a Phase 2 clin­i­cal tri­al that’s test­ing a drug from De­nali for mul­ti­ple scle­ro­sis, putting a stop to the de­vel­op­ment plan. … ...

Exscientia (NASDAQ:EXAI – Get Free Report) and Quince Therapeutics (NASDAQ:QNCX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two ...

Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...

Many current AI successes, like those of Exscientia, rely on technologies developed over a decade ago in academic settings; long-term investment was required to achieve the impressive speed of ...

France will take a stake in Sanofi’s (SNY) Opella through the Public Investment Bank, or BPI, finance minister Antoine Armand said on Sunday, confirming an information from Le Figaro newspaper ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

Exscientia plc (Nasdaq: EXAI) today announced the advancement of two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving an aggregate of $15 million in ...

PAI Partners increased its offer for Sanofi's (NASDAQ:SNY) consumer health unit. The private equity shop raised its offer by about €200 million ($217 million) for the Opella business and pledged ...

The new entity focuses on the discovery, design and development of RLTs. Credit: PeopleImages.com – Yuri A/Shutterstock. Sanofi and Orano Group subsidiary Orano Med have announced a partnership to ...